KRAS and neoplasm: AZD4785 was identified as a lead compound out of 2160 ASOs and was selected based on its activity in cells and xenograft models; systemic delivery of AZD4785 to mice bearing KRAS-mutant NSCLC xenografts or patient-derived xenografts resulted in inhibition of KRAS tumour expression and subsequent anti-tumour activity (20).